Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06955923 · ClinicalTrials.gov registry record · Phase 2
Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty
A Phase 2 study of Trigger Point Pain, Myofascial, sponsored by David Grant U.S. Air Force Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT06955923: Completed Phase 2 study of Trigger Point Pain, Myofascial, sponsored by David Grant U.S. Air Force Medical Center.
NCT06955923 is a Phase 2 study of Trigger Point Pain, Myofascial that has completed, run by David Grant U.S. Air Force Medical Center. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06955923, a Phase 2 study of Trigger Point Pain, Myofascial, has completed, sponsored by David Grant U.S. Air Force Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the ability of trigger point injections completed immediately following a total knee arthroplasty decrease pain scores and opioid use compared to sham injections. Given the current state of opioid dependency in the United States there needs to be a more focused attempt at treating post-operative pain without use of opioids. Given the manipulation of soft tissue during a total knee arthroplasty there seems to be a high correlation with pain and myofascial pain syndrome. This study will include an experimental (trigger point injection) and control (sham injection) group who are all undergoing a total knee arthroplasty. This is a pilot study that will include a maximum of 100 total patients (although it is planned for the study to be much smaller with a planned 10-15 patients per group). The procedure that will be completed is a trigger point injection with use of 1% lidocaine without epinephrine along the distal aspect of the vastus medialis and lateralis, proximal aspect of the medial and lateral gastrocnemius muscle bellies. The sham injection will be completed by pressing the needle against the skin without injecting any fluid. There will be a "blind" between the patient and the needle with both arms of the study. These patients will be followed up on POD1, and during weeks 2 and 6 follow-up where they will be given questionnaires to assess pain (visual analogue scale) and opioid use, and asked to bring their opioid medications to the clinic to assess the morphine milligrams equivalent (MME).
Primary Outcome
1\. Change in Visual Analog Scale (VAS) pain scores The VAS is a numbered scale assessing pain severity using a number which describes the average level of pain since being discharged. Participants are to put a hash mark "/" on a numbered scale ranging from 0-100. Zero (0) is no pain and 100 is severe intolerable pain
Conditions Studied
Interventions
- OTHER Sham Comparator
- DRUG Trigger point injection (lidocaine)
Study Locations (1)
California
- David Grant Medical Center - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2025-08-26 |
| Phase | Phase 2 |
What the finished NCT06955923 record still lists
NCT06955923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Trigger Point Pain, Myofascial appearing as the primary indexed condition, and to 2 interventions - of which Sham Comparator is the first listed.
NCT06955923 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06955923 about?
NCT06955923 is a clinical study titled "Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty". This study will evaluate the ability of trigger point injections completed immediately following a total knee arthroplasty decrease pain scores and opioid use compared to sham injections. Given the current state of opioid dependency in the United States there needs to be a more focused attempt at tr...
What is the current status of trial NCT06955923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2025-05-30. Estimated completion is 2025-08-26.
What conditions does trial NCT06955923 study?
This clinical trial studies the following conditions: Trigger Point Pain, Myofascial.
What interventions are being tested in trial NCT06955923?
The interventions under investigation include: Sham Comparator (OTHER), Trigger point injection (lidocaine) (DRUG).
Who is sponsoring clinical trial NCT06955923?
This trial is sponsored by David Grant U.S. Air Force Medical Center, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06955923 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trigger Point Pain, Myofascial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06955923's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI